

Mohammed Abdul Rasheed

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1376428/publications.pdf>

Version: 2024-02-01

9
papers

144
citations

1684188

5
h-index

1474206

9
g-index

9
all docs

9
docs citations

9
times ranked

238
citing authors

#	ARTICLE	IF	CITATIONS
1	Synthesis and SAR of Imidazo[1,5-a]pyridine derivatives as 5-HT ₄ receptor partial agonists for the treatment of cognitive disorders associated with Alzheimer's disease. <i>European Journal of Medicinal Chemistry</i> , 2015, 103, 289-301.	5.5	46
2	Discovery and Development of 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1 <i>H</i> -indole Dimesylate Monohydrate (SUVN-502): A Novel, Potent, Selective and Orally Active Serotonin 6 (5-HT ₆) Receptor Antagonist for Potential Treatment of Alzheimer's Disease. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 1843-1859.	6.4	38
3	Synthesis, Structure-Activity Relationships, and Preclinical Evaluation of Heteroaromatic Amides and 1,3,4-Oxadiazole Derivatives as 5-HT ₄ Receptor Partial Agonists. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 4993-5008.	6.4	27
4	In-vivo rat striatal 5-HT ₄ receptor occupancy using non-radiolabelled SB207145. <i>Journal of Pharmacy and Pharmacology</i> , 2013, 65, 704-712.	2.4	10
5	Discovery and Preclinical Characterization of Usmarapride (SUVN-D4010): A Potent, Selective 5-HT ₄ Receptor Partial Agonist for the Treatment of Cognitive Deficits Associated with Alzheimer's Disease. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 10641-10665.	6.4	8
6	Benzamide derivatives and their constrained analogs as histamine H ₃ receptor antagonists. <i>European Journal of Medicinal Chemistry</i> , 2016, 108, 655-662.	5.5	5
7	Absorption, distribution, metabolism, excretion (ADME), drug-drug interaction potential and prediction of human pharmacokinetics of SUVN-G3031, a novel histamine 3 receptor (H ₃ R) inverse agonist in clinical development for the treatment of narcolepsy. <i>European Journal of Pharmaceutical Sciences</i> , 2020, 152, 105425.	4.0	5
8	First-in-Human Studies to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Novel 5-HT ₄ Partial Agonist, SUVN-D4010, in Healthy Adult and Elderly Subjects. <i>Clinical Drug Investigation</i> , 2021, 41, 469-482.	2.2	4
9	A selective and accurate liquid chromatography-tandem mass spectrometry method for the quantitation of the novel 5-HT ₄ receptor partial agonist SUVN-D4010 (Usmarapride) in human plasma and urine. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2022, 211, 114617.	2.8	1